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T he definition of male hypogonadism, used in adult endocrinology, is not fully applicable to paediatrics. A clear understanding of the developmental physiology of the hypothalamic-pituitary-testicular axis is essential for the comprehension of the pathogenesis of hypogonadal states in boys and for the establishment of adequate definitions and classifications in paediatric ages. This is particularly 
true for central hypogonadism, usually called hypogonadotropic in adults. Because childhood is a period characterised by a physiological state 
of low gonadotropin and testosterone production, these markers of hypogonadism, typically used in adult endocrinology, are uninformative 
in the child. This review is focused on the physiological importance of prepubertal Sertoli cell markers – anti-Müllerian hormone (AMH) and 
inhibin B – and of the intratesticular actions of follicle-stimulating hormone (FSH) and testosterone during early infancy and the first stages 
of pubertal development. We discuss the role of FSH in regulating the proliferation of Sertoli cells – the main determinant of prepubertal 
testicular volume – and the secretion of AMH and inhibin B. We also address how intratesticular testosterone concentrations have different 
effects on the seminiferous tubule function in early infancy and during pubertal development.
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In the adult male, hypogonadism is usually defined by the failure of the testis to produce 
physiological concentrations of testosterone and/or a normal number of spermatozoa.1 
When due to abnormalities of the hypothalamic-pituitary axis, the condition is referred to as 
hypogonadotropic or central hypogonadism, whereas those due to testicular defects are called 
hypergonadotropic or primary hypogonadism. However, these definitions are inadequate for most 
paediatric conditions. Indeed, during the largest part of infancy and childhood, the hypothalamic-
gonadotroph axis is quiescent and the testes produce neither spermatozoa nor detectable 
amounts of testosterone. A more adapted definition and classification of male hypogonadism is 
based on the developmental physiology of the gonadal axis.2 Accordingly, the definition should be 
extended to any decreased testicular function as compared to what is expected for age, involving 
impaired hormone secretion by Leydig cells (i.e., androgens, insulin-like 3 [INSL3]), Sertoli cells 
(i.e., anti-Müllerian hormone [AMH], inhibin B) and/or a disorder of spermatogenesis. Moreover, 
it should be emphasised that primary hypogonadism rarely presents with elevated gonadotropin 
levels3 and even anorchidism might present with normal gonadotropin levels in about 30–60% 
of the cases during childhood,4 indicating that the term hypergonadotropic hypogonadism may 
be misleading in paediatrics. Additionally, since circulating gonadotropin concentrations are low 
in the normal prepubertal boy, it is difficult to demonstrate the existence of levels below normal, 
thus making the term hypogonadotropic hypogonadism also inadequate.
A clear understanding of the developmental physiology of the hypothalamic-pituitary-testicular 
axis is essential for the comprehension of the pathogenesis of hypogonadal states in paediatric 
ages (Figure 1). Under hypothalamic control, the gonadotrophs secrete luteinizing hormone (LH) 
and follicle-stimulating hormone (FSH) during the second and third trimesters of foetal life, and 
also during the first 3–6 months after birth – a period usually referred to as mini-puberty.5,6 LH 
induces Leydig cell activation, resulting in testosterone production at levels that are similar to 
those of the adult. Androgens are responsible for testicular descent and penile growth. FSH 
induces Sertoli cell proliferation7 and since Sertoli cells represent the largest part of testicular 
mass before puberty, FSH is the main factor regulating testicular volume (Figure 2). Sertoli cells 
produce peptide hormones, such as inhibin B and AMH. Although their basal production is 
gonadotropin-independent, there is clinical8–10 and experimental evidence11,12 that FSH increases 
Sertoli cell secretion of inhibin B and AMH.
Around birth, there is a transient decrease in gonadotropin and testicular hormone levels,13 but from 
the second week of postnatal life, all hormone levels increase and remain high for 3–6 months.6 
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Thereafter and during the rest of infancy and childhood, LH and 
testosterone decrease to very low or undetectable levels. FSH and 
inhibin B also decrease but remain clearly detectable.14 Conversely, 
AMH peaks in the first year and remains high during childhood15,16 until 
it decreases in puberty inhibited by testosterone.17 In spite of the high 
levels of testosterone that seminiferous cords are exposed to during 
the foetal and postnatal periods, no signs of maturation are observed 
in Sertoli and germ cells. This is explained by the fact that Sertoli cells 
are physiologically insensitive to testosterone because the androgen 
receptor is not expressed in Sertoli cells until the second year of postnatal 
life (Figure 1).18 In fact, when elevated androgen levels abnormally persist 
beyond the age of 1 year (e.g. in boys with central precocious puberty), 
clear signs of Sertoli cell maturation appear.19
The onset of puberty is characterised by the increase in gonadotropin 
pulse frequency and amplitude. FSH further boosts testicular volume 
to >4 cc (Figure 2). LH reawakens Leydig cell activity, leading initially 
to an increase in intratesticular testosterone concentration which 
provokes Sertoli cell maturation: they stop dividing and decrease 
their expression of AMH.5 Mature Sertoli cells are able to sustain 
spermatogenesis;20 the completion of this process leads to sperm 
production and also results in the remarkable increase of testicular 
volume to 15–25 cc. The elevation of serum testosterone and the 
resulting development of secondary sexual characteristics is a relatively 
late event in boys.
Central hypogonadism in boys
Aetiology
Congenital central hypogonadism
Congenital central (“hypogonadotropic”) hypogonadism reflects the 
failure of the pituitary to produce sufficient amounts of gonadotropins. 
Most frequently, it is caused by deficient production, secretion or action 
of gonadotropin-releasing hormone (GnRH).21 The condition can be 
isolated and it is known as isolated hypogonadotropic hypogonadism,22 
or associated to other pituitary hormone deficiencies.23 Several 
gene defects have been described as the cause of gonadotropin 
insufficiency. The pathogenesis may be related to: 1) altered GnRH 
neuron formation in the olfactory placode or its migration to the 
hypothalamus (usually associated with hyposmia/anosmia and known 
as Kallmann syndrome), 2) abnormal GnRH production due to defects 
in regulatory factors or in the GnRH1 gene, and 3) defective action in 
the gonadotroph owing to abnormalities in the GnRH receptor or its 
transduction pathway.21,22 Extremely rare are mutations in the genes 
encoding the beta subunits of LH or FSH.24 Finally, genes associated 
with defective formation of the hypothalamic-pituitary region have 
been described in a low proportion of cases with multiple pituitary 
hormone deficiency.25
Acquired central hypogonadism
Of all paediatric and pubertal forms of central hypogonadism, 
approximately 20% are of functional origin. In these cases, a chronic 
illness or an underlying stressor causes the suppression of gonadotropin 
secretion and the condition can be reverted when the chronic illness is 
adequately treated.26 Conversely, permanent forms are due to conditions 
affecting the hypothalamic-pituitary area, e.g. high radiation doses, 
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Figure 1: Serum levels of reproductive axis hormones in 
the male
Figure 2: Schematic representation of the association 
between testicular volume and hormonal changes during 
postnatal development
Schematic of the ontogeny of serum levels of reproductive axis hormones from 
foetal life through adulthood and its association with physiological events of the 
reproductive tract development. AMH = anti-Müllerian hormone; AR = androgen 
receptor; FSH = follicle-stimulating hormone; LH = luteinizing hormone; MD regr = 
regression of Müllerian ducts (anlagen of the uterus and Fallopian tubes) occurring 
in response to AMH; mo = months; Trim = trimester of foetal life; WD & EG diff = 
differentiation of Wolffian ducts (anlagen of the epididymis, vas deferens and seminal 
vesicles) and external genitalia, occurring in response to testosterone. Modified with 
permission from Grinspon et al., 2014.28
During infancy and childhood, there is little change in testicular volume, which 
depends mainly on Sertoli cell number. From a clinical standpoint, when testicular 
volume reaches 4 cc the boy is said to have started pubertal development (Tanner 
stage two). This is due mainly to Sertoli cell proliferation in response to increased 
FSH activity. Concomitantly, LH induces Leydig cell testosterone secretion, resulting 
in an increase in intratesticular testosterone concentration. This leads to Sertoli cell 
maturation (reflected by a decrease in AMH secretion and an increase in inhibin B, 
during Tanner stages two to three) and the development of full adult spermatogenesis, 
the main responsible for testicular volume growth between pubertal Tanner stages 
two to five. Subsequently, testosterone also increases in serum (Tanner stages 
three to five). AMH = anti-Müllerian hormone; FSH = follicle-stimulating hormone; 
LH = luteinizing hormone; T = testosterone; TV = testicular volume. Modified with 
permission from Edelsztein et al., 2016.31




The insufficiency of LH and testosterone during the second half of foetal 
life usually results in micropenis, cryptorchidism and hypoplastic scrotum. 
On the other hand, FSH insufficiency leads to microorchidism due to 
Sertoli cell hypoplasia. Midline defects and signs like hypoglycaemia 
or jaundice can orientate to multiple pituitary hormone deficiencies. 
Unfortunately, the insufficient attention given to cardinal features, such 
as micropenis, cryptorchidism, cleft lip/palate, deafness, coloboma, etc., 
in the newborn or infant results in missing the window of opportunity for 
the diagnosis during the postnatal activation period.
Prepubertal age
Since changes in testicular volume and penile size are minimal during 
childhood, acquired central hypogonadism established in this period of 
life may go underdiagnosed even if the underlying aetiology is evident, 
e.g. tumours or surgery of the central nervous system.
Pubertal age
Absence of pubertal signs is the main feature of complete forms of 
central hypogonadism, whereas delayed onset or progression, or even 
arrest of pubertal development, may be indicative of partial forms. At 




The window of opportunity for confirming central hypogonadism using 
gonadotropin and testosterone measurements in term newborns and 
infants resides between the third week and the third month. Indeed, in 
the first 2 weeks, gonadotropins and testosterone may still be low and 
only starting to increase after the perinatal nadir in normal newborns,13 
thus hormone values should be interpreted cautiously in order to avoid 
false positive diagnoses. Similarly, from the fourth to sixth month onwards, 
gonadotropins and testosterone may already be decreasing physiologically. 
During the post-natal active period, or mini-puberty, low LH and testosterone 
have high positive predictive values for central hypogonadism.23,27–29
If the diagnosis was not certified before the sixth month of age, LH and 
testosterone levels are no longer informative until pubertal age. Although 
FSH is usually neglected in the study of male central hypogonadism, 
circulating levels never drop to undetectable during childhood and 
can therefore be more informative than LH. Indeed, in a series of boys 
presenting without spontaneous pubertal development, basal FSH had a 
higher predictive value than LH for the diagnosis of central hypogonadism.30
Sertoli cell markers
As already mentioned, AMH and inhibin B are Sertoli cell products, whose 
basal production is independent of gonadotropins. Nevertheless, FSH is 
capable of increasing inhibin B8,9 and AMH9,10 testicular secretion, thus 
indicating that they both are good markers of FSH action on the testis.31 
The increased AMH testicular output in response to FSH in prepubertal 
male patients reflects two effects of FSH on immature Sertoli cells. On 
one hand, FSH induces Sertoli cell proliferation,7 which explains that FSH 
treatment in newborns or infants causes an increase in testicular volume.9 
AMH levels reflect the amount of functional Sertoli cells in different 
conditions.32–34 On the other hand, using two experimental models, 
knockout mice null for the gene encoding the FSH beta subunit12 and the 
prepubertal Sertoli cell lineage SMAT1 expressing AMH,35 we showed that 
FSH upregulates the AMH promoter activity signalling through the cyclic 
AMP-mediated pathway, mainly via protein kinase A activity.36,37
The aforementioned regulation of Sertoli cells by FSH during foetal life and 
the neonatal period explains the findings of microorchidism and low serum 
AMH and inhibin B in boys with congenital central hypogonadism.8,9,23,29,38
Treatment
Testosterone
In patients with congenital central hypogonadism, the presence of 
micropenis may prompt testosterone treatment. When the diagnosis is 
made at birth – or more rarely during childhood – depot testosterone 
(testosterone enanthate or cypionate) at 25–50 mg/dose intramuscular 
(IM) every 4 weeks for 3 consecutive months may be sufficient to 
normalise penile size without provoking an advancement of bone 
age.39 In older boys with central hypogonadism reaching the age of puberty, 
steroid replacement is necessary for the development of secondary sex 
characteristics, the acquisition of full bone mass and the optimisation 
of height velocity, as well as for avoiding psychosocial distress. Depot 
testosterone is given at 50 mg IM each month for 6–12 months, with a 
subsequently progressive dose escalation until a full dose of 250 mg/
month in 2–3 years. The aim is to mimic normal pubertal tempo. When full 
pubertal development is attained, treatment should be switched to follow 
standards for adults.1 Alternative approaches include oral androgens 
such as testosterone undecanoate40 and transdermal gels.41,42
Gonadotropins
Exogenous testosterone supplementation aims to attain physiological 
circulating androgen levels. However, physiological intratesticular 
testosterone concentration is never reached with these treatments, 
whose disadvantages are that Sertoli cells neither proliferate nor 
mature and, subsequently, adult spermatogenesis does not develop. 
In fact, testicular volume remains small (<4 cc) in patients receiving only 
testosterone treatment.
Treatment with pulsatile GnRH or combined gonadotropins is well 
established in adult patients with central hypogonadism seeking fertility.21 
Conversely, limited information is available on the use of gonadotropins 
in paediatric patients.43 Observational studies on infants with congenital 
central hypogonadism suggest that the postnatal peak in reproductive 
hormones plays an important role in genital development.44 Therefore, 
various authors have proposed the use of gonadotropins during infancy, 
instead of testosterone, to mimic mini-puberty in patients with congenital 
central hypogonadism. A case report describes an infant treated from 
the age of 7.9 months with recombinant human (rh) LH (subcutaneous 
injections 20 IU twice a week) and FSH (subcutaneous injections 2.5 IU/kg 
twice a week).45 Testicular volume increased 170%, reflecting FSH action 
on Sertoli cells. 
A case series reports eight patients aged 0.25–11 months who received 
continuous infusion of rhLH and rhFSH with insulin pumps at a daily rate 
of 50 and 75–150 IU, respectively.9 Testicular hormones reached “mini-
puberty” levels, complete testis descent occurred in six patients and 
partial descent in two, and testes and penis reached normal dimensions 
in all cases. Similar results were observed in patients receiving continuous 
subcutaneous infusion of rh gonadotropins.46 Even though long-term 
follow-up is needed to fully evaluate the outcomes of this therapeutic 
approach, these results suggest that subcutaneous gonadotropin 
infusion is able to induce not only Sertoli cell proliferation and function 
but also testis descent in patients with congenital central hypogonadism, 
thus avoiding surgical treatment.47
Only one study reports prepubertal treatment with rhFSH of three 
boys with central hypogonadism.8 In this case, the rationale was that 
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FSH would be capable of inducing Sertoli cell multiplication before 
they mature at puberty. The boys were given rhFSH subcutaneously 
(1.5 IU/kg) three times a week for 12 months. Treatment induced testicular 
growth and inhibin B production, reflecting stimulation of immature 
Sertoli-cell function. These findings suggest that FSH treatment in 
childhood is capable of inducing Sertoli-cell proliferation, which may 
result in an increased sperm-producing capacity in adulthood.
Finally, several publications exist on combined recombinant 
gonadotropin treatment for the induction of puberty in boys with 
central hypogonadism. Some of them used the standard protocols for 
adults initiating with human chorionic gonadotropin (hCG) and then 
adding rhFSH48,49 and showed acceptable results. Moreover, in studies 
using initial priming with rhFSH prior to induction of puberty with the 
combination of rhFSH and hCG, rhFSH induced prepubertal testicular 
growth and increased serum levels of AMH (Figure 3)10 and inhibin 
B levels (Figure 4),10,50 confirming the importance of FSH action on 
immature Sertoli cells. The addition of hCG resulted in a progressive 
increase in testosterone production, Sertoli cell maturation suggested 
by an important decrease in serum AMH and acquisition of sperm 
production.10 Also, the increase of inhibin B proved useful for 
monitoring spermatogenic development.50 More recently, an open-
label randomised study in hypogonadal males aged >18 years showed 
better results in men receiving rhFSH pre-treatment in terms of 
spermatogenic development.51
Concluding remarks
While LH and testosterone levels have been used for years in the diagnosis 
of central hypogonadism at pubertal age and adulthood, in paediatric 
patients they are useful only during the early post-natal activation period. 
During childhood, low levels of the Sertoli cell markers AMH and inhibin 
B support the diagnosis of central hypogonadism. Furthermore, although 
testosterone replacement therapies have been used for many years with 
satisfactory results on the development of secondary sex characteristics 
in adolescents with central hypogonadism, more recently the attention 
has been driven to the physiological importance of the intratesticular 
actions of FSH and testosterone during early infancy and the first stages 
of pubertal development.
The limited number of studies available to date demonstrate that a 
sequential treatment approach with rhFSH priming to induce Sertoli 
cell proliferation, before adding hCG or rhLH to provoke an increase in 
intratesticular testosterone concentration and Sertoli cell maturation, 
shows encouraging results in terms of induction of testicular growth 
and sperm production.8,10,50,51 To definitively prove the superiority of this 
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Figure 3: Effect of sequential rhFSH and hCG treatment 
on AMH and testosterone in patients with central 
hypogonadism
Figure 4: Effect of sequential rhFSH and hCG treatment 
on inhibin B and testicular volume in patients with central 
hypogonadism
Initial treatment with rhFSH for 30 days provoked an elevation of serum AMH, while 
testosterone remained at prepubertal levels. Shaded area represents normal AMH 
levels for boys with low testosterone (corresponding to pubertal Tanner stage one). 
Subsequent addition of hCG induced an elevation of T, which provoked a decline 
in serum AMH. Shaded area represents normal AMH values for Tanner stages 4–5, 
according to the T levels observed in the treated patients. *p<0.05; **p<0.01; 
***p<0.001. AMH = anti-Müllerian hormone; hCG = human chorionic gonadotropin; 
rhFSH = recombinant human follicle-stimulating hormone; T = testosterone. 
Modified with permission from Young et al., 2005.10
Effect of rhFSH and FSH plus hCG treatments on serum inhibin B levels (top) and testis 
volume (bottom) in boys with prepubertal onset of gonadotropin deficiency. *p<0.01; 
†p<0.005; ‡p<0.001. FSH = follicle-stimulating hormone; hCG = human chorionic 
gonadotropin; rhFSH = recombinant human follicle-stimulating hormone. Modified with 
permission from Raivio et al., 2007.50
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